Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 159

1.

Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration.

Jilka RL, Almeida M, Ambrogini E, Han L, Roberson PK, Weinstein RS, Manolagas SC.

Aging Cell. 2010 Oct;9(5):851-67. doi: 10.1111/j.1474-9726.2010.00616.x.

PMID:
20698835
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton.

Almeida M, Ambrogini E, Han L, Manolagas SC, Jilka RL.

J Biol Chem. 2009 Oct 2;284(40):27438-48. doi: 10.1074/jbc.M109.023572. Epub 2009 Aug 5.

PMID:
19657144
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Glucocorticoids and tumor necrosis factor α increase oxidative stress and suppress Wnt protein signaling in osteoblasts.

Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC.

J Biol Chem. 2011 Dec 30;286(52):44326-35. doi: 10.1074/jbc.M111.283481. Epub 2011 Oct 26.

PMID:
22030390
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.

Weinstein RS, Jilka RL, Almeida M, Roberson PK, Manolagas SC.

Endocrinology. 2010 Jun;151(6):2641-9. doi: 10.1210/en.2009-1488. Epub 2010 Apr 21.

PMID:
20410195
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1.

Bodine PV, Seestaller-Wehr L, Kharode YP, Bex FJ, Komm BS.

J Cell Physiol. 2007 Feb;210(2):352-7.

PMID:
17044082
[PubMed - indexed for MEDLINE]
6.

Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts.

Jilka RL, O'Brien CA, Ali AA, Roberson PK, Weinstein RS, Manolagas SC.

Bone. 2009 Feb;44(2):275-86. doi: 10.1016/j.bone.2008.10.037. Epub 2008 Oct 22.

PMID:
19010455
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.

Iida-Klein A, Lu SS, Cosman F, Lindsay R, Dempster DW.

Bone. 2007 Feb;40(2):391-8. Epub 2006 Oct 20.

PMID:
17056311
[PubMed - indexed for MEDLINE]
8.

The effect of aging on the skeletal response to intermittent treatment with parathyroid hormone.

Knopp E, Troiano N, Bouxsein M, Sun BH, Lostritto K, Gundberg C, Dziura J, Insogna K.

Endocrinology. 2005 Apr;146(4):1983-90. Epub 2004 Dec 23.

PMID:
15618351
[PubMed - indexed for MEDLINE]
9.

Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH.

Li C, Xing Q, Yu B, Xie H, Wang W, Shi C, Crane JL, Cao X, Wan M.

J Bone Miner Res. 2013 Oct;28(10):2094-108. doi: 10.1002/jbmr.1962.

PMID:
23609180
[PubMed - indexed for MEDLINE]
10.

Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL.

J Biol Chem. 2003 Dec 12;278(50):50259-72. Epub 2003 Oct 1.

PMID:
14523023
[PubMed - indexed for MEDLINE]
Free Article
11.

Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone.

Pennisi A, Ling W, Li X, Khan S, Wang Y, Barlogie B, Shaughnessy JD Jr, Yaccoby S.

PLoS One. 2010 Dec 20;5(12):e15233. doi: 10.1371/journal.pone.0015233.

PMID:
21188144
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.

Iida-Klein A, Zhou H, Lu SS, Levine LR, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R.

J Bone Miner Res. 2002 May;17(5):808-16.

PMID:
12009011
[PubMed - indexed for MEDLINE]
13.

Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.

Schneider MR, Dahlhoff M, Andrukhova O, Grill J, Glösmann M, Schüler C, Weber K, Wolf E, Erben RG.

Bone. 2012 Jan;50(1):237-44. doi: 10.1016/j.bone.2011.10.019. Epub 2011 Oct 26.

PMID:
22056328
[PubMed - indexed for MEDLINE]
14.

The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.

Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH.

J Biol Chem. 2006 Aug 18;281(33):23698-711. Epub 2006 Jun 20.

PMID:
16790443
[PubMed - indexed for MEDLINE]
Free Article
15.

Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH.

Bedi B, Li JY, Tawfeek H, Baek KH, Adams J, Vangara SS, Chang MK, Kneissel M, Weitzmann MN, Pacifici R.

Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):E725-33. doi: 10.1073/pnas.1120735109. Epub 2012 Mar 5.

PMID:
22393015
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms.

Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC.

J Bone Miner Res. 2010 Nov;25(11):2427-37. doi: 10.1002/jbmr.145.

PMID:
20533302
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration.

Ogita M, Rached MT, Dworakowski E, Bilezikian JP, Kousteni S.

Endocrinology. 2008 Nov;149(11):5713-23. doi: 10.1210/en.2008-0369. Epub 2008 Jul 10.

PMID:
18617606
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).

Wang L, Quarles LD, Spurney RF.

J Bone Miner Res. 2004 Oct;19(10):1661-70. Epub 2004 Jul 14.

PMID:
15355561
[PubMed - indexed for MEDLINE]
19.

Mitogen-activated protein kinase phosphatase 1 regulates bone mass, osteoblast gene expression, and responsiveness to parathyroid hormone.

Mahalingam CD, Datta T, Patil RV, Kreider J, Bonfil RD, Kirkwood KL, Goldstein SA, Abou-Samra AB, Datta NS.

J Endocrinol. 2011 Nov;211(2):145-56. doi: 10.1530/JOE-11-0144. Epub 2011 Aug 18.

PMID:
21852324
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment.

Liu F, Lee SK, Adams DJ, Gronowicz GA, Kream BE.

Bone. 2007 Apr;40(4):1135-43. Epub 2007 Feb 1.

PMID:
17275432
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk